Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
Status:
Terminated
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well erlotinib hydrochloride works in treating
patients with bladder cancer undergoing surgery. Erlotinib hydrochloride may stop the growth
of tumor cells by blocking some of the enzymes needed for cell growth.